Acebutolol Inhibitor

Acebutolol is a cardioselective beta-1 adrenergic antagonist with antiarrhythmic and hypotensive activity and little effect on the bronchial receptors. Acebutolol has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.

Khalit WN, Tay KS. Aqueous chlorination of acebutolol: kinetics, transformation by-products, and mechanism. Environ Sci Pollut Res Int. 2015 Oct 1. [Epub ahead of print] PubMed PMID: 26423291.
Muta K, Fukami T, Nakajima M. A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production. Biochem Pharmacol. 2015 Sep 25. pii: S0006-2952(15)00626-7. doi: 10.1016/j. Bcp.2015.09.016. [Epub ahead of print] PubMed PMID: 26408002.
Banoth L, Thakur NS, Bhaumik J, Banerjee UC. Biocatalytic Approach for the Synthesis of Enantiopure Acebutolol as a beta1-Selective Blocker. Chirality. 2015 Jun;27(6):382-91. doi: 10.1002/chir.22444. Epub 2015 May 15. PubMed PMID: 25977108.
Ogrodowczyk M, Dettlaff K, Kachlicki P, Marciniec B. Identification of Radiodegradation Products of Acebutolol and Alprenolol by HPLC/MS/MS. J AOAC Int. 2015 Jan-Feb;98(1):46-50. doi: 10.5740/jaoacint.14-096. PubMed PMID: 25857877.

Small volumes of Acebutolol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756717 is an inhibitor targeting Acebutolol.